Co-administration of pramlintide and insulin via an automated dual-hormone artificial pancreas system to regulate glucose levels in type 1 diabetes: a 4-week, outpatient, randomized, controlled, crossover trial

通过自动双激素人工胰腺系统联合施用普兰林肽和胰岛素来调节 1 型糖尿病患者的血糖水平：一项为期 4 周的门诊、随机、对照、交叉试验

• 批准号: 402199
• 负责人: Haidar Ahmad
• 金额: $ 30.93万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2021-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=402199&lang=en
• 关键词: Amylin; Artificial Pancreas Systems; Clinical Trial; Diabetes Technology; Glucose Sensors; Insulin Pump; Type 1 Diabetes

Insulin-alone artificial pancreas systems improve glucose control compared to conventional pump therapy but clinically significant hyperglycemia (5 to 8 hours per day) still exist. Pramlintide is a drug and an analog of amylin, a hormone that is co-secret

与传统泵治疗相比，单独使用胰岛素的人工胰腺系统改善了血糖控制，但仍存在临床显著的高血糖（每天5至8小时）。普兰林肽是一种药物，也是胰淀素的类似物，胰淀素是一种激素，